Interestingly, the DLGAP5-mutant group had a higher probability of tumor mutation burden (TMB) (Figure 7(c)), a quantifiable biomarker for immune checkpoint blockade (ICB) selection. This evidence concerns the gene DLGAP5 and neoplasm.